The 20 Largest Medical Device Companies In the World

Share

Zimmer Biomet logoNo. 15: Zimmer Biomet

Warsaw, Ind.

www.zimmerbiomet.com

2016 RANK: 19

Revenue: $7,683,900,000

Fiscal year ending: Dec. 31, 2016

Employees: 18,500

R&D Spend: $365,600,000

 

Key Personnel:

Daniel Florin, interim CEO, SVP & CFO; Tony Collins, VP, controller & chief accounting officer; Derek Davis, VP, global integration; Robert Delp, president, Americas; William (Bill) Fisher, SVP, global HR; Adrian Furey, SVP, global operations & logistics; Adam Johnson, president, spine, dental, CMF & thoracic; David Kunz, SVP, global quality & regulatory affairs; Dr. Katarzyna Mazur-Hofsaess, president, EMEA; David Nolan, president, biologics, extremities, sports medicine, surgical, trauma, foot & ankle, office-based technologies & Zimmer Biomet signature solutions; Chad Phipps, SVP, general counsel & secretary; Daniel Williamson, president, joint reconstruction; Sang Yi, president, Asia Pacific

Description:

Zimmer Biomet has had a hectic year, with 10-year veteran David Dvorak abruptly stepping away from the corner office in July and senior VP and CFO Daniel Florin stepping in until a replacement is found.

Dvorak hasn’t been the only employee to exit the company, which said it “cleaned house” at certain Warsaw-based facilities after receiving a number of violations during an FDA inspection.

The purge included replacing the company’s senior vice president of global operations and logistics, vice president of quality assurance at all of its Warsaw sites, the quality assurance director for its North Campus facilities, the compliance director for the Biomet network, and the quality assurance director for post-market surveillance and complaint handling.

Download the full Big 100 list here.

And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!

Next>>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11

Comments

  1. Chris Newmarker says:

    Apologies. We had to fix a technical glitch with the Big 100 spreadsheet download. If you fill out the sign-up form now, you should get an email with a link to download the spreadsheet, instead of last year’s Big 100 edition.

  2. Chris, Thank you for the update. I just downloaded the Big 100.

Speak Your Mind

*